RT Journal Article
SR Electronic
T1 TRENDS IN CASES, HOSPITALISATION AND MORTALITY RELATED TO THE OMICRON BA.4/BA.5 SUB-VARIANTS IN SOUTH AFRICA
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.08.24.22279197
DO 10.1101/2022.08.24.22279197
A1 Jassat, Waasila
A1 Abdool Karim, Salim S
A1 Ozougwu, Lovelyn
A1 Welch, Richard
A1 Mudara, Caroline
A1 Masha, Maureen
A1 Rousseau, Petro
A1 Wolmarans, Milani
A1 Selikow, Anthony
A1 Govender, Nevashan
A1 Walaza, Sibongile
A1 Gottberg, Anne von
A1 Wolter, Nicole
A1 Pisa, Pedro Terrence
A1 Sanne, Ian
A1 Govender, Sharlene
A1 DATCOV author group
A1 Blumberg, Lucille
A1 Cohen, Cheryl
A1 Groome, Michelle J.
YR 2022
UL http://medrxiv.org/content/early/2022/08/25/2022.08.24.22279197.abstract
AB Introduction The Omicron BA.1/BA.2 wave in South Africa had lower hospitalisation and mortality than previous SARS-CoV-2 variants and was followed by an Omicron BA.4/BA.5 wave. This study compared admission incidence risk across waves, and the risk of mortality in the Omicron BA.4/BA.5 wave, to the Omicron BA.1/BA.2 and Delta waves.Methods Data from South Africa’s national hospital surveillance system, SARS-CoV-2 case linelist and Electronic Vaccine Data System were linked and analysed. Wave periods were defined when the country passed a weekly incidence of 30 cases/100,000 people. Mortality rates in the Delta, Omicron BA.1/BA.2 and Omicron BA.4/BA.5 wave periods were compared by post-imputation random effect multivariable logistic regression models.Results In-hospital deaths declined 6-fold from 37,537 in the Delta wave to 6,074 in the Omicron BA.1/BA.2 wave and a further 7-fold to 837 in the Omicron BA.4/BA.5 wave. The case fatality ratio (CFR) was 25.9% (N=144,798), 10.9% (N=55,966) and 7.1% (N=11,860) in the Delta, Omicron BA.1/BA.2, and Omicron BA.4/BA.5 waves respectively. After adjusting for age, sex, race, comorbidities, health sector and province, compared to the Omicron BA.4/BA.5 wave, patients had higher risk of mortality in the Omicron BA.1/BA.2 wave (adjusted odds ratio [aOR] 1.43; 95% confidence interval [CI] 1.32-1.56) and Delta (aOR 3.22; 95% CI 2.98-3.49) wave. Being partially vaccinated (aOR 0.89, CI 0.86-0.93), fully vaccinated (aOR 0.63, CI 0.60-0.66) and boosted (aOR 0.31, CI 0.24-0.41); and prior laboratory-confirmed infection (aOR 0.38, CI 0.35-0.42) were associated with reduced risks of mortality.Conclusion Overall, admission incidence risk and in-hospital mortality, which had increased progressively in South Africa’s first three waves, decreased in the fourth Omicron BA.1/BA.2 wave and declined even further in the fifth Omicron BA.4/BA.5 wave. Mortality risk was lower in those with natural infection and vaccination, declining further as the number of vaccine doses increased.Competing Interest StatementThe authors have declared no competing interest.Funding StatementROLE OF THE FUNDING SOURCE DATCOV as a national surveillance system, was initially funded by the NICD and the South African National Government, and subsequently by the support of the American people through the United States Agency for International Development (USAID) via the mechanism awarded to Right to Care. The contents of this study are the sole responsibility of the NICD and NDoH and do not necessarily reflect the views of USAID, PEPFAR, or the United States Government. The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was obtained from the Human Research Ethics Committee (Medical) of University of the Witwatersrand for the collection of COVID-19 case data (M210752), and for the DATCOV surveillance programme (M2010108).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe dataset analysed for the manuscript is available upon reasonable request. The data dictionary is available at request to the corresponding author: waasilaj{at}nicd.ac.za